Journal of pharmaceutical and biomedical analysisComplement C1qInterferometryTrastuzumabHumansProtein Binding
Qualification and robustness study of a bio-layer interferometry-based C1q binding assay for therapeutic antibodies.
Defeng Jiao, Yunfeng Hu, Lijuan Liao, Hejian Zhang, Lili Wang, Yongsheng Xiao, Jun Tian
Published: 202610.1016/j.jpba.2025.117229
Abstract
Bio-layer interferometry (BLI) assays have been widely used to study the interaction between therapeutic antibodies and complement component 1q protein (C1q), assessing the efficiency of antibody-induced complement-dependent cytotoxicity (CDC). In th…
Preview only. Read the full abstract at the source